Adjuvant radiotherapy versus early salvage radiotherapy in prostate cancer
Paul Sargos (Institut Bergonié, France) discusses the GETUG-AFU 17 trial and Andrew Kneebone (Royal North Shore Hospital and University of Sidney, Australia) the RAVES trial. Tell us what you thought about this episode Continue this conversation on social! Follow us today at... https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thela...